Zoprinea

MK-Zoprinea-N-09/2016

,
M

2
 ?

3

4
-
,
,

2 5

1
3


,,
4-72

2-3

/

4



,

5
 ?
12% (30 ) *

20-55

(17%) (6%)

12%

10%

8%
12% 12%
6%

4% 6% 6%

2%
1%
0%

6 | Business Use Only

*
 ?

29% 25% 1 /

28%

34% >50%

48%

| American Migraine Prevalence and Prevention study results (Lipton RB et al. Neurology. 2007;68:343-349).

7




( , ,
)


(, ),
(, , , ), ,
.

8 | Business Use Only



9 | Business Use Only

 2-3

o 5-20 1 20 %
1. , ,-
, -
2. j 2/3 e

3. 18%
,,,
70 %
a
,,
 *


60 %
menstrual migraine** (36%)***
1/3

( ()

)

G ranella F et al. Headache. 1993;33:385-389. Couturier EGM et al.

Cephalalgia. 2003;23:302-308. MacGregor EA. J Fam Plan Reprod Health Care.
2007;33:36-47.*Dzoljic. MacGregor EA et al. Neurology. 2006;67:2154-2158.
MacGregor EA, Hackshaw A. Neurology. 2004;63:351-353. NHF. Women & Migraine.
www.headaches.org.** NHF. Migraine: Not Just a Womans Disease. www.headaches.org***.

| Business Use Only

 ?

12 | Business Use Only

EBM Guidelines ( Cochrane)

1. Paracetamol
2. spirin
3. ( )
metoclopramide
,

,

13

,
A.

14

1.
Almotriptan Rizatriptan
Eletriptan Sumatriptan

Frovatriptan Zolmitriptan
Naratriptan (Amerge)

2. (DHE)

3. (acetaminophen,ibuprofen,naproxen
aspirin/acetaminophen/caffeine)

15 | Business Use Only



5-HT1B/1D

-

-zolmitriptan
(5HT1) .


(calcitonin gene related peptide (CGRP),
(VIP) P.
, ,
40%
(N-desmethyl metabolit)
5HT1B/1D 2 6
Cmax 1








2
.

>10 mg

.
 Promo material

1. Data on file Lek Skopje DOOEL 2014; 2. Mollie M.Johnston and Alan M.Rapoport,Triptans for
management of Migraine,Drugs2010;70(12):1505-1518, 3. Peter J.Goadsby and
Christopher J.Boes.Zolmitriptan:Di.erences from Sumatriptan,Current medical research and
opinion Vol17,2001,s46-50
 >20.000
1

1. Bird.S,Derry.S,Moore.R,21May 2014 , 4. Gallager RM,Dennish G,Spierings EL,Chitra R.A comparative

trial of zomitriptan and sumatriptan for the acute treatment of migraine.Headache .2000;40:119-128
 ?

Data on
le Lek Skopje DOOEL 2014;

22 | Business Use Only